Karl Deisseroth, MD, PhD

Founder & Scientific Advisor

Dr. Karl Deisseroth, professor of bioengineering and psychiatry at Stanford University, founded ClearLight based on the CLARITY lipid-clearing technique he and colleagues invented and developed at Stanford University. Dr. Deisseroth has a long list of publications, honors and awards, including the 2015 Lurie Prize in Biomedical Sciences for the development of CLARITY and optogenetics. His scientific achievements have spawned additional research and methods that have revolutionized the study of the brain and have led to major advances in neuroscience and biomedical engineering. He continues to serve ClearLight Biotechnologies as a Scientific Advisor.

“We need to take big risks and even blind leaps.”

Karl Deisseroth, MD, PhD Founder & Scientific Advisor - ClearLight Biotechnologies

Follow Dr. Deisseroth on twitter at @KarlDeisseroth

Multidisciplinary Inventor

“CLARITY is a way of transforming complex biological systems into a very accessible and informative state.

It’s been a very long held goal in biology. What CLARITY provides is a way of not having to disassemble the tissue. That addresses the challenge of reassembly and reconstruction process, both the practical aspect and the scientific aspect”

A Look Inside the Brain

A New Experimental Approach at the Interface of Chemistry and Biology Lets Scientists Peer into the Deepest Reaches of the Body's Master Controller

- by Karl Deisseroth
Scientific American

Practitioner and Pioneer

Karl Deisseroth is the D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences at Stanford University, and Investigator of the Howard Hughes Medical Institute. He received his undergraduate degree from Harvard, his PhD from Stanford, and his MD from Stanford; he also completed postdoctoral training, medical internship, and adult psychiatry residency at Stanford, and he is board-certified by the American Board of Psychiatry and Neurology. He continues as a practicing psychiatrist at Stanford with specialization in affective disorders and autism-spectrum disease, employing medications along with neural stimulation.

Over a period of twelve years, his laboratory created and developed optogenetics, hydrogel-tissue chemistry (beginning with CLARITY), and a broad range of supportive and enabling methods. He also has employed his technologies to discover the neural cell types and connections that cause adaptive and maladaptive behaviors and has disseminated the technologies to thousands of laboratories around the world.

For his discoveries, Deisseroth has received the NIH Director's Pioneer Award (2005), the Zuelch Prize (2012), the PerlPrize (2012), the BRAIN prize (2013), the Pasarow Prize (2013), the Breakthrough Prize (2015) the BBVA Award (2016), the Massry Prize (2016) and the Harvey Prize from the Technion/Israel (2017), and among other honors, was the sole recipient for optogenetics of the 2010 Koetser Prize, the 2010 Nakasone Prize, the 2011 Alden Spencer Prize, the 2013 Richard Lounsbery Prize, the 2014 Dickson Prize in Science, the 2015 Keio Prize, the 2015 Lurie Prize, the 2015 Albany Prize, the 2015 Dickson Prize in Medicine, the 2017 Redelsheimer Prize, the 2017 Fresenius Prize, the 2017 NOMIS Distinguished Scientist Award, the 2018 Eisenberg Prize, and the 2018 Kyoto Prize. He was selected a Howard Hughes Medical Institute Investigator in 2013, and was elected to the US National Academy of Medicine in 2010, to the US National Academy of Sciences in 2012 and to the National Academy of Engineering in 2019.

Enabling Modern Heroes. Perhaps YOU are one.

Thankfully researchers like you are involved in drug discovery and development. If your research work will benefit from non-destructive tissue processing and True 3D spatial image analysis let’s work together on new possibilities. We want to hear from you and answer your questions about the next dimension in spatial analysis.

Call (800) 251-8905

Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: